Depiperazine-DM3189
Depiperazine-DM3189 is a derivative of LDN193189 (HY-12071). LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva.
For research use only. We do not sell to patients.
- CAS No.: 1062368-55-1
- Formula: C21H14N4
- Molecular Weight:322.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Chemical Information
-
CAS No. 1062368-55-1
-
Molecular Weight 322.36
-
Formula C21H14N4
-
SMILES
C1(C2=C3N=CC(C4=CC=CC=C4)=CN3N=C2)=CC=NC5=CC=CC=C15
-
Synonyms
Depiperazine-LDN-193189
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14(12), 1363-1369. [Content Brief]
[2]. Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290(6):3390-404. [Content Brief]
[3]. Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Depiperazine-DM3189 Related Classifications
HY-17661 Related Classifications
Powered by Bioz